VDPHL01 is an oral, non-hormonal treatment for androgenetic alopecia developed by Veradermics. Phase 2/3 results are in; the drug is not yet approved and not yet on sale. This page tracks every milestone — clinical, regulatory, commercial — until launch.
Phase 01
Safety established
Completed
Phase 02
Positive topline: +30.3 hairs/cm²
Apr 27, 2026
Phase 03
Fully enrolled, results pending
H2 2026 readout
Phase 04
Submission to FDA
Early 2027 (est.)
Phase 05
Regulatory decision
Late 2027 (est.)
Phase 06
On-market availability
2027–2028 (est.)
Launch alert
Get the launch alertOne email the day VDPHL01 goes on sale. That's the promise.
The most common questions about VDPHL01 — short answers, links to detail.
Estimated late 2027 to early 2028, pending Phase 3 '304' results and FDA approval.
Not on the market yet. After FDA approval it will be sold through licensed pharmacies only.
Not announced. Analysts project $200–400/month at launch — well above generic finasteride.
An oral, non-hormonal AGA treatment by Veradermics. Protects follicles without altering hormones.
Side-by-side with finasteride, dutasteride, topical/oral minoxidil, clascoterone, pyrilutamide.
A reformulated oral minoxidil. The drug drives blood flow to follicles; a gel-matrix flattens the plasma peaks behind cardiac side effects of standard oral minoxidil.
Announced by Veradermics on April 27, 2026. The trial met all primary and key secondary endpoints.
Hair density change at 6 months — Study '302' QD arm vs placebo
Sources: Business Wire press release · ClinicalTrials.gov NCT06724614
Chronological log of Veradermics announcements and trial milestones.
VDPHL01 met the primary endpoint in the female arms of open-label Study '207'. Once-daily oral dosing produced a statistically significant and clinically meaningful increase in nonvellus target area hair count at week 24 — the first controlled efficacy data for the drug in women. Veradermics hosts an investor call on July 15 to review the data.
Read the resultsVDPHL01 met all primary and key secondary endpoints. Patients on the once-daily dose gained +30.3 hairs/cm² vs +7.3 for placebo; 79–86% reported improvement. Statistically significant hair growth observed as early as Month 2. No cardiac adverse events reported. Veradermics shares rose 48% on the announcement.
Read full breakdownVeradermics announced completion of enrollment in its second pivotal Phase 3 trial for male pattern hair loss. Approximately 1,000 male patients enrolled across studies. Topline data from '304' expected H2 2026.
Study 304 detailsAnswers to the most common search queries about VDPHL01.
In Phase 2/3 Study '302', VDPHL01 demonstrated a clean safety profile with no cardiac adverse events reported. Because the drug does not interact with the hormonal system, the libido and erectile-dysfunction concerns associated with 5-alpha reductase inhibitors such as finasteride have not been observed in trials. Full safety data will be published in peer-reviewed journals before NDA submission.
No, not yet. VDPHL01 has completed Phase 2/3 Study '302' with positive topline results (April 2026). A confirmatory Phase 3 trial ('304') is ongoing, with topline data expected in H2 2026. NDA submission to the FDA is anticipated in early 2027.
A separate Phase 3 trial ('306', NCT07146022) in female pattern hair loss is actively recruiting. Results will determine whether VDPHL01 is approved for women as well as men. Both indications follow independent regulatory pathways.
Yes. If approved, VDPHL01 will require a physician's prescription — consistent with how oral minoxidil is currently managed off-label and similar to finasteride. It will not be available over the counter.
We'll send one email when VDPHL01 becomes available to buy. Rare milestone notes in between — only if something material happens.